Marijuana Rescheduling: What DC Medical Cannabis Businesses Need to Know

For years, DC's medical cannabis industry has operated under a strange split: legal and licensed at the District level, but still federally illegal under the Controlled Substances Act. A recent DEA rule addressing marijuana's federal scheduling status, and creating a new registration pathway for state-licensed cannabis businesses, is a significant development for DC operators. Here's what has actually happened, and why it matters.

What Changed

DEA and DOJ issued a final rule, effective April 28, 2026, rescheduling certain marijuana products from Schedule I to Schedule III of the Controlled Substances Act. Importantly, this rule reaches beyond FDA-approved cannabis pharmaceuticals. It specifically covers marijuana subject to a state medical marijuana license, defined broadly enough to include a license issued by a District of Columbia entity. In plain terms, cannabis businesses holding a DC medical cannabis license, cultivators, manufacturers, and dispensaries, fall within the scope of this rescheduling action, not just federally approved drug products like Marinol.

The New Registration Pathway

Alongside the rescheduling, DEA created an expedited registration process for entities holding a state (or DC) medical marijuana license. Under this pathway, a business can submit proof of its DC license as conclusive evidence of state-law authorization, and DEA is generally required to grant the registration unless doing so would be inconsistent with the public interest. This is a meaningfully lower bar than the standard DEA registration process, and it allows state-licensed operators to rely on their existing DC licensing, packaging, security, and labeling compliance rather than building a separate federal compliance framework from scratch.

One important detail: DEA registration under this pathway is tied to the underlying DC license. If that license is suspended, revoked, or lapses, the DEA registration is automatically suspended along with it.

Timing Matters

DEA stated it would process applications submitted within 60 days of the rule's publication within six months, and that businesses applying within that window could continue operating under their DC license while the application was pending. Because the rule was published in late April 2026, that 60-day window has already closed. Businesses that haven't yet applied should not assume the same expedited treatment or interim operating protection still applies. If your business hasn't started this process, it's worth getting an assessment of where you stand now.

A Meaningful Tax Consequence

One of the more immediately impactful changes for cannabis businesses is on the tax side. Schedule I status has historically triggered Section 280E, which disallows standard business expense deductions for marijuana businesses, an enormous financial burden in an already high-overhead industry. Businesses operating under the new Schedule III framework are positioned to no longer be subject to that deduction disallowance, though DEA has been clear that this rule itself doesn't resolve every federal tax question, and businesses should coordinate with their tax advisors on how this applies to their specific situation.

What This Doesn't Do

It's worth being precise about what this rule does not do. It does not legalize recreational or unlicensed marijuana at the federal level; that remains Schedule I. It's also separate from a broader, ongoing administrative proceeding regarding marijuana's overall scheduling status, which has been working through its own hearing process. Businesses should be cautious about conflating these developments, they involve different scopes, different procedural postures, and potentially different timelines.

What This Means for DC Operators

For DC's licensed cultivators, manufacturers, and dispensaries, this rule represents the clearest federal pathway to date toward operating with some measure of federal recognition, potential tax relief, and reduced legal exposure. But the details, licensing status, application timing, and how DEA registration interacts with DC's own regulatory framework, matter enormously to how this plays out for any individual business.

If you operate in DC's medical cannabis space and want to understand how this rule affects your business specifically, now is a good time to have that conversation.

This post is intended for general informational purposes and reflects our understanding of a rapidly evolving regulatory area as of this writing. It does not constitute legal advice, and readers should consult an attorney regarding how these developments apply to their specific business and circumstances.